A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine

Jun Ho Yi; Silvia Park; Jung Han Kim; Young-Woong Won; Do Hyoung Lim; Boram Han; Jieun Uhm; Hae Su Kim; Chul Won Jung; Jun Ho Jang

doi:10.18632/oncotarget.23823

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine

Jun Ho Yi, Silvia Park, Jung Han Kim, Young-Woong Won, Do Hyoung Lim, Boram Han, Jieun Uhm, Hae Su Kim, Chul Won Jung and Jun Ho Jang _

PDF | HTML | How to cite

Oncotarget. 2018; 9:6607-6614. https://doi.org/10.18632/oncotarget.23823

Metrics: PDF 1313 views | HTML 2278 views | ?

Abstract

Jun Ho Yi1, Silvia Park2, Jung Han Kim3, Young-Woong Won4, Do Hyoung Lim5, Boram Han6, Jieun Uhm7, Hae Su Kim8, Chul Won Jung2 and Jun Ho Jang2

1Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea

2Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

3Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Korea

4Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea

5Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea

6Department of Internal Medicine, Hallym University Medical Center, Hallym University, Hallym University College of Medicine, Anyang, Korea

7Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Korea

8Division of Hematology-Oncology, Department of Internal Medicine, VHS Medical Center, Seoul, Korea

Correspondence to:

Jun Ho Jang, email: [email protected]

Keywords: acute myeloid leukemia; elderly patients; decitabine

Received: February 10, 2017 Accepted: December 26, 2017 Published: January 02, 2018

ABSTRACT

Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0–15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23823

Publication Alerts

Clinical Research Papers:

A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine

Abstract